MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

• Status: Completed
• Trial end date: 2009-10-23
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Metformin; Pioglitazone; Sitagliptin Phosphate

Criteria

General Inclusion Criteria:

• Patient has type 2 diabetes mellitus

• Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy

General Exclusion Criteria:

• Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

• Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 12 weeks

• Patient was on >4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin) over the prior 3 years